Re: What's New in Pediatric Dermatology?

View this email in your browser Journal Publications Keywords: Acne (3), Psoriasis (3), Atopic Dermatitis, Pediatric (2), Alopecia (1), Comedonal Acne (1), Cystic Acne (1), Hemangioma (1) 1. JAMA dermatology Aug 1, 2019 Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis.JAMA Dermatol. 10.1001/jamadermatol.2019.1946Margolis DJ, Mitra N, Wubbenhorst B,D'Andrea K, Kraya AA, Hoffstad O,Shah S, Nathanson KL View Journal Article on Derm101                                       2. Paediatric drugs Aug 1, 2019 New and Emerging Therapies for Pediatric Atopic Dermatitis.Paediatr Drugs. 10.1007/s40272-019-00342-wNguyen HL, Anderson KR, Tollefson MM View Journal Article on Derm101                                       3. American family physician Jul 31, 2019 Infantile Hemangioma: AAP Releases Guideline for Management.Am Fam Physician. ;100(3):186-187Hoover L View Journal Article on Derm101                                       4. Clinical case reports Jul 31, 2019 Erythematous scaling lesions of the face, dorsal fingers, elbows, and knees together with symmetrical muscle weakness in a child.Clin Case Rep. ;7(7):1347-1349. 10.1002/ccr3.2219Markovic A, Schuster V, Simon JC,Kunz M View Journal Article on Derm101                                       5. The Journal of clinical and aesthetic dermatology Jul 31, 2019 Patient Awareness of Antimicrobial Resistance and Antibiotic Use in Acne Vulgaris.J Clin Aesthet Dermatol. ;12(6):30-41Del Rosso JQ, Rosen T, Palceski D,Rueda MJ View Journal Article on Derm101                                       6. Pediatric dermatology Jul 30, 2019 Erosive pustular dermatosis of the scalp in an adolescent with near-total hair regrowth: Case report and review of the literature.Pediatr Dermatol. 10.1111/pde.13929Teng C, Yu J, Taylor J, Rubin AI, Treat JR View Journal Article on Derm101                                       7. Journal of psoriasis and psoriatic arthritis Jul 30, 2019 Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities.J Psoriasis Psoriatic Arthritis. ;3(4):131-136. 10.1177/2475530318799072Brandon TG, Manos CK, Xiao R,Ogdie A, Weiss PF View Journal Article on Derm101                                       8. Acta dermatovenerologica Croatica : ADC Jul 29, 2019 Adalimumab - Safe and Effective Therapy for an Adolescent Patient with Severe Psoriasis and Immune Thrombocytopenia.Acta Dermatovenerol Croat. ;27(2):121-123Sikora M, Gajda P, Chrabąszcz M,Stec A, Olszewska M, Rudnicka L View Journal Article on Derm101                                       9. Acta dermatovenerologica Croatica : ADC Jul 29, 2019 Correlation between Family History and the Age of Onset of Childhood Acne in Relation to Sex and Type of Acne.Acta Dermatovenerol Croat. ;27(2):86-89Šijak D, Horvat I, Sonicki Z, Murat-Sušić S, Husar K, Skerlev M,Marinović B, Bukvić Mokos Z View Journal Article on Derm101                                       10. Acta dermatovenerologica Croatica : ADC Jul 29, 2019 High Body Mass Index is a Risk Factor for Acne Severity in Adolescents: A Preliminary Report.Acta Dermatovenerol Croat. ;27(2):81-85Sas K, Reich A View Journal Article on Derm101                                       More Journal Publications on Derm101 Clinical Trials Keywords: Neurofibromatosis (3), Atopic Dermatitis, Pediatric (1), Plaque Psoriasis (1), Psoriasis (1) 1. National Institutes of Health Clinical Center (CC) Last changed Jul 30, 2019 Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas              Conditions Neurofibromatosis Type I Plexiform Neurofibroma Interventions Drug: Nexavar (BAY 43-9006) (Sorafenib) Drug: Toxicity, Pharmacokinetics Drug: Pharmacodynamics Drug: Radiographic Evaluation Drug: QOL assessment, Neuropsychological Drug: Bony Toxicity Study Type Interventional Phase Phase 1 Recruitment Status complete [9 patients] View Clinical Trial on Derm101                                       2. Regeneron Pharmaceuticals Last changed Jul 30, 2019 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Conditions Atopic Dermatitis Interventions Drug: Dupilumab Study Type Interventional Phase Phase 3 Recruitment Status ongoing [765 patients] View Clinical Trial on Derm101                                       3. National Cancer Institute (NCI) Last changed Jul 29, 2019 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Conditions Advanced Malignant Solid Neoplasm ARAF Gene Mutation BRAF Gene Mutation GNA11 Gene Mutation GNAQ Gene Mutation HRAS Gene Mutation KRAS Gene Mutation MAP2K1 Gene Mutation MAPK1 Gene Mutation NF1 Gene Mutation NRAS Gene Mutation Recurrent Ependymal Tumor Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Histiocytic and Dendritic Cell Neoplasm Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Central Nervous System Neoplasm Recurrent Malignant Germ Cell Tumor Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma Recurrent Osteosarcoma Recurrent Peripheral Primitive Neuroectodermal Tumor Recurrent Rhabdoid Tumor Recurrent Rhabdomyosarcoma Recurrent Soft Tissue Sarcoma Refractory Ependymoma Refractory Ewing Sarcoma Refractory Glioma Refractory Hepatoblastoma Refractory Histiocytic and Dendritic Cell Neoplasm Refractory Langerhans Cell Histiocytosis Refractory Malignant Central Nervous System Neoplasm Refractory Malignant Germ Cell Tumor Refractory Malignant Solid Neoplasm Refractory Medulloblastoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Osteosarcoma Refractory Peripheral Primitive Neuroectodermal Tumor Refractory Rhabdoid Tumor Refractory Rhabdomyosarcoma Refractory Soft Tissue Sarcoma Wilms Tumor Interventions Other: Pharmacokinetic Study Drug: Ulixertinib Study Type Interventional Phase Phase 2 Recruitment Status ongoing [49 patients] View Clinical Trial on Derm101                                       4. National Cancer Institute (NCI) Last changed Jul 29, 2019 Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Conditions Advanced Malignant Solid Neoplasm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma BRAF Gene Mutation GNA11 Gene Mutation GNAQ Gene Mutation Histiocytosis HRAS Gene Mutation KRAS Gene Mutation NF1 Gene Mutation NRAS Gene Mutation Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Refractory Central Nervous System Neoplasm Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Interventions Other: Laboratory Biomarker Analysis Drug: Selumetinib Drug: Selumetinib Sulfate Study Type Interventional Phase Phase 2 Recruitment Status ongoing [49 patients] View Clinical Trial on Derm101                                       5. AbbVie Last changed Jul 24, 2019 Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea Conditions Psoriasis Interventions Study Type Observational Phase Recruitment Status ongoing [1 patients] View Clinical Trial on Derm101                                       More Clinical Trials on Derm101

This email was sent to bhidalgo@gmail.com  why did I get this?    unsubscribe from this list    update subscription preferences  Derm101 · 430 East 29th Street · New York, NY 10016 · USA